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As structural membrane components and signaling effector molecules sphingolipids
influence a plethora of host cell functions, and by doing so also the replication of
viruses. Investigating the effects of various inhibitors of sphingolipid metabolism in
primary human peripheral blood lymphocytes (PBL) and the human B cell line BJAB
we found that not only the sphingosine kinase (SphK) inhibitor SKI-II, but also the acid
ceramidase inhibitor ceranib-2 efficiently inhibited measles virus (MV) replication. Virus
uptake into the target cells was not grossly altered by the two inhibitors, while titers
of newly synthesized MV were reduced by approximately 1 log (90%) in PBL and 70–
80% in BJAB cells. Lipidomic analyses revealed that in PBL SKI-II led to increased
ceramide levels, whereas in BJAB cells ceranib-2 increased ceramides. SKI-II treatment
decreased sphingosine-1-phosphate (S1P) levels in PBL and BJAB cells. Furthermore,
we found that MV infection of lymphocytes induced a transient (0.5–6 h) increase in S1P,
which was prevented by SKI-II. Investigating the effect of the inhibitors on the metabolic
(mTORC1) activity we found that ceranib-2 reduced the phosphorylation of p70 S6K in
PBL, and that both inhibitors, ceranib-2 and SKI-II, reduced the phosphorylation of p70
S6K in BJAB cells. As mTORC1 activity is required for efficient MV replication, this effect
of the inhibitors is one possible antiviral mechanism. In addition, reduced intracellular
S1P levels affect a number of signaling pathways and functions including Hsp90 activity,
which was reported to be required for MV replication. Accordingly, we found that
pharmacological inhibition of Hsp90 with the inhibitor 17-AAG strongly impaired MV
replication in primary PBL. Thus, our data suggest that treatment of lymphocytes with
both, acid ceramidase and SphK inhibitors, impair MV replication by affecting a number
of cellular activities including mTORC1 and Hsp90, which alter the metabolic state of
the cells causing a hostile environment for the virus.
Keywords: measles virus, sphingolipids, acid ceramidase, acid ceramidase inhibitor ceranib-2, sphingosine
kinase, sphingosine kinase inhibitor SKI-II
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INTRODUCTION
Sphingolipids are major membrane lipid constituents and as
such, their biogenesis, modifications, and turnover are tightly
linked to all processes involving membrane dynamics and the
cellular metabolism. Their local segregation and metabolites
directly affect biophysical properties of membranes including
membrane deformation, fusion, and vesicle formation, however,
they also act as signal transducing molecules. Being used
as signaling molecules, they govern the metabolic state and
fundamental host cell responses such as apoptosis, survival,
autophagy, and proliferation (Hannun and Obeid, 2008).
Therefore, sphingolipids and their metabolites are potential key
regulators in the life cycle of obligatory intracellular pathogens
such as viruses, which rely on cellular metabolism.
Several findings revealing effects of the sphingolipid
metabolism on viral infections came from animal models
(Schneider-Schaulies and Schneider-Schaulies, 2015). Acid
sphingomyelinase (ASM)-deficient mice are more susceptible
to Sindbis virus-induced encephalomyelitis (Ng and Griffin,
2006; Ng et al., 2008), ceramides enhance the infection with
Japanese encephalitis virus (Takamatsu et al., 2010), and CD8+
T cells of lymphocytic choriomeningitis virus (LCMV)-infected
ASM-deficient mice secrete reduced levels of IFN-γ and cytotoxic
granules resulting in delayed viral clearance (Herz et al., 2009).
In addition, certain viruses such as major- and minor-group
human rhinoviruses are able to promote the formation of
ceramide-enriched membrane platforms thereby supporting
their own entry into target cells (Grassme et al., 2005). Similarly,
MV induces surface expression of its receptor CD150 via DC-
SIGN-mediated activation of sphingomyelinases in dendritic
cells, and thereby stimulates its own uptake into these cells
(Avota et al., 2011). Adenovirus stimulates calcium influx and
lysosomal exocytosis, a membrane repair mechanism resulting
in the release of ASM and degradation of sphingomyelin (SM)
to ceramides in the plasma membrane (Luisoni et al., 2015).
Furthermore, SM and ASM activity appear to be involved in early
steps of Ebola virus infection. In addition, the endo/lysosomal
cholesterol transporter NPC1 residing in an intracellular
compartment rather than at the plasma membrane serves as
an entry receptor for Ebola virus (Miller et al., 2012). We
found that MV brain infection in ASM-deficient mice, or after
pharmacological inhibition of the ASM in mice, is enhanced
due to an increased frequency of CD4+ Foxp3+ regulatory
T cells (Hollmann et al., 2016). These findings highlight the
potential of manipulations of the sphingolipid metabolism for
novel therapeutic or immunomodulatory applications against
viral infections.
In order to investigate the interference of sphingolipid
metabolism with a viral infection, we used measles virus
(MV) infection of lymphocytes as a model system. During
the infection of a person MV first interacts with the receptor
CD150 on the surface of macrophages, dendritic cells, as well
as activated and memory B and T cells and is predominantly
taken up by pH-independent receptor-mediated membrane
fusion at the plasma membrane (Tatsuo et al., 2000; Erlenhoefer
et al., 2001). Later, the virus interacts with nectin-4 to
infect polarized epithelial cells (Muhlebach et al., 2011; Noyce
et al., 2011). Despite the availability of an effective vaccine,
measles remains a leading cause of mortality and morbidity
in young children causing approximately 100,000 deaths each
year worldwide (World Health Organization [WHO], 2018).
The infection is associated with a number of complications
including immunosuppression, and may also persist and
cause subacute sclerosing panencephalitis (SSPE) (Reuter and
Schneider-Schaulies, 2010; Mina et al., 2015). A specific antiviral
therapy is not yet available. However, several compounds
manipulating sphingolipid metabolism are available, and some
of them are already in clinical use mainly applied against
various forms of cancer. We wondered, if such drugs could
also be used to manipulate MV replication. Vijayan et al.
(2014) recently described that overexpression of the SphK-1
enhanced, and inhibition of SphK-1 (and -2) by the inhibitor
SKI-II reduced MV replication in epithelial and lymphoid
cell lines. They found that after MV infection of these cell
lines the activity of the sphingosine kinases (SphK) and the
phosphorylation of NF-kB p65 was increased. Furthermore,
the NF-kB inhibitor Bay-11-7082 also reduced MV protein
synthesis by preventing the phosphorylation and subsequent
degradation of IkB (Vijayan et al., 2014). Accordingly, S1P-
metabolizing enzymes reduced influenza virus (IAV) propagation
and cytopathogenicity (Seo et al., 2010).
In the present study we investigated if some well-known
inhibitors of the sphingolipid metabolism, which are partially
already in clinical use, may inhibit MV replication in its primary
natural target cells, i.e., CD150+ cells. We found that not only
SKI-II (French et al., 2003; Draper et al., 2011), but also ceranib-
2 (Draper et al., 2011), an inhibitor of the acid ceramidase,
efficiently reduced MV replication in primary human PBL
and the human B cell line BJAB. The data suggest that MV
replication can be impaired by several mechanisms regulated by
sphingolipid-mediated signaling pathways.
MATERIALS AND METHODS
Cells, Viruses, and Inhibitors
All experiments involving human cells were conducted according
to the principles expressed in the Declaration of Helsinki
and ethically approved by the Ethics Committee of the
Medical Faculty of the University of Würzburg. Primary
human peripheral blood mononuclear cells (PBMCs) obtained
from leuko-reduction chambers of thrombocyte donations
of anonymous healthy adult volunteers were diluted 1:6 in
Versene (Gibco), layered on Histopaque R© 1077 and purified
by density gradient centrifugation. Isolated PBMCs were
washed three times with (PBL) and suspended in RPMI 1640
(Gibco) medium containing 10% FBS and incubated for 2 h
on plastic dishes to remove adherent monocytes. Peripheral
blood lymphocytes (PBL) were collected and stimulated with
phytohemagglutinin-L (PHA, 2.5 µg/ml, Roche). Stimulation was
controlled by measuring CD69 expression by flow cytometry.
The human B cell line BJAB was cultivated using RPMI 1640
medium containing 5% FBS. The recombinant wild-type MV
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rMVIC323eGFP (Hashimoto et al., 2002) was propagated using
Vero cells expressing CD150 (Vero-hSLAM). For the described
experiments, cells were infected for 2 h, washed with PBS,
and further incubated for indicated times in medium. Virus
was harvested by freezing and thawing the complete cultures,
thus cell-associated and supernatant virus were harvested
together, and titrated using Vero-hSLAM cells. The inhibitors
of SphK-1 and -2, SKI-II, of acid ceramidase, ceranib-2, of
ASM, amitriptyline, of NSM, GW4869, and of Hsp90, 17-
AAG, were purchased from Sigma–Aldrich. All inhibitors except
amitriptyline were dissolved in dimethyl sufoxide (DMSO). The
viability of cells in the presence of inhibitors was determined
after 48 h incubation by flow cytometry using propidium iodide
(PI; Biolegend) staining for dead cells. The percentage of dead
cells in the presence of corresponding concentrations DMSO
was subtracted from values obtained for various concentrations
of inhibitors and the viability in the presence of 0.2% DMSO
normalized to 100%.
Antibodies and Flow Cytometry
The following primary antibodies were used in immunoblotting
and flow cytometry: rabbit anti-GAPDH (Santacruz), rabbit
anti-phospho-p70 S6 kinase (S6K) (Thr 389) (Cell Signaling),
rabbit anti-p70 S6K (Cell Signaling), and APC-conjugated anti-
human CD69 (Biolegend). Anti-human CD150 antibody clone
5C6 was generated in our laboratory (Erlenhoefer et al., 2001).
The following labeled secondary antibodies were used: Alexa488-
conjugated anti-mouse (Life Technology), Alexa594-conjugated
anti-rabbit (Life Technology), and horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (Cell Signaling). For flow
cytometry 2 × 105 cells per sample were stained with respective
antibodies in FACS buffer (PBS containing 0.4% bovine serum
albumin (BSA) and 0.02% sodium azide). Dead cells were stained
with PI (Biolegend). Cells were acquired immediately using a LSR
II flow cytometer (BD) and the data were analyzed using FlowJo
(Cytek Development) software.
Virus Uptake Assay
To measure virus uptake, cells were pretreated with increasing
concentrations of inhibitors as indicated for 1 h prior to infection
with MV (MOI = 0.5 for primary PBL and MOI = 0.1 for BJAB
cells) for 2 h at 37◦C. Then the cells were washed with PBS
and further incubated in medium for 22 h at 37◦C to allow
viral transcription and protein expression. The percentage of
infected (viral eGFP-positive) cells was then determined by flow
cytometry (not the mean fluorescence intensity which reflects the
amount of viral protein expression).
SDS-PAGE and Immunoblotting
Cells (5 × 106) were lysed at 4◦C for 1 h in 1 ml of
lysis buffer [50 mM Tris–HCl, pH 8.0, 150 mM sodium
chloride (NaCl), 1.0% Igepal CA-630 (NP-40), 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS)] containing
complete protease inhibitor cocktail (Sigma–Aldrich) and 1 mM
DL-dithiothreitol (DTT). The protein quantification was done
using the bicinchoninic acid (BCA) assay. An equal amount
of proteins was heated at 95◦C for 5 min in reducing sample
buffer (50 mM Tris–HCl, pH 6.8, 2% SDS, 10% glycerol,
1% β-mercaptoethanol, 12.5 mM ethylenediaminetetraacetic
acid (EDTA), 0.02% bromophenol blue) and applied to 12%
SDS-polyacrylamide gel electrophoresis. Proteins were blotted
semidry on nitrocellulose membranes (Amersham) followed by
blocking with 5% dry milk (AppliChem) or 5% BSA in Tris-
buffered saline with 0.05% Tween-20. The membranes were
then incubated with specific primary antibodies and HRP-
conjugated secondary antibodies. Signals were visualized using
Chemiluminescent FemtoMaxTM Super Sensitive HRP Substrate
(Rockland). The densitometric quantification of protein bands
of target proteins and respective housekeeping gene were done
using Li-Cor Odyssey Pc imaging System Image Studio Version
4.0 (Li-Cor Biosciences). The fold changes in target proteins were
normalized to band densities of respective GAPDH and fold
changes in phosphorylated proteins were normalized to the band
densities of total protein or GAPDH levels. All western blotting
experiments were repeated at least three times and representative
images are shown.
Lipid Analysis
For lipid analysis 8 × 106 PBL or 1 × 106 BJAB cells per
sample were resuspended in 500 µl methanol and subsequently
subjected to lipid extraction using methanol/chloroform (2:1,
v:v) (Gulbins et al., 2018). The extraction solvent contained d7-
Sph, d7-sphingosine-1-phosphate (d7-S1P), C17-ceramide, and
C16-d31-SM (all Avanti Polar Lipids, Alabaster, United States)
as internal standards. Sample analysis was carried out by liquid
chromatography tandem–mass spectrometry (LC–MS/MS) using
either a TQ 6490 mass spectrometer (for Sph and S1P) or a
QTOF 6530 mass spectrometer (for ceramides and SMs) (Agilent
Technologies) operating in the positive electrospray ionization
mode (ESI+). The following selected reaction monitoring (SRM)
transitions were used for quantification: m/z 300.3→ 282.3 for
Sph, m/z 380.3 → 264.3 for S1P, m/z 307.3 → 289.3 for d7-
Sph, and m/z 387.3→ 271.3 for d7-S1P. The precursor ions of
ceramide or SM species (differing in their fatty acid chain lengths)
were cleaved into the fragment ions m/z 264.270 or m/z 184.074,
respectively (Kachler et al., 2017). Quantification was performed
with Mass Hunter Software (Agilent Technologies).
Statistical Analysis
Statistical analysis was performed using Microsoft Excel or
GraphPad Prism 6. Two groups were analyzed using unpaired
two-tailed Student’s t-test and more than two groups were
analyzed with one-way ANOVA. P-values lower than or equal
to 0.05 were considered statistically significant (∗P ≤ 0.05,
∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001). The data represent mean ± SD of at
least three independent experiments.
RESULTS
The Sphingosine Kinase Inhibitor SKI-II
Inhibits MV Replication in Primary
Human PBL
Peripheral blood lymphocytes from healthy donors were
stimulated with PHA for 24 h prior to treatment with inhibitors
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 October 2019 | Volume 7 | Article 218
fcell-07-00218 September 28, 2019 Time: 18:30 # 4
Grafen et al. Measles Virus–Sphingolipid Interactions
and infection with MV. Their activation, infection, and viability
in the presence of inhibitors were controlled by flow cytometry
(Figures 1A–C). A representative control showing 24 h PHA-
stimulated PBL, which were subsequently infected for 48 h with
MV at a MOI of 0.1 is given in Figure 1A. We were using PHA-
stimulated PBL since stimulation increases the titer of newly
synthesized MV approximately 20-fold (Figure 1B). The viability
of PHA-stimulated PBL was determined using PI in the presence
of increasing concentrations of SKI-II (Figure 1C). In further
experiments we used 1 and 5 µM SKI-II, concentrations at which
≥95 and ≥85%, respectively, of PBL were viable.
To determine the effect of SphK inhibition on MV replication,
PBL from six healthy donors were infected with MV at a MOI
of 0.1 in the absence and presence of 0, 1, and 5 µM of SKI-II,
and the newly synthesized MV (cell bound plus supernatant) was
prepared and titrated after 1, 2, and 3 days (Figure 1D). The
viral titers were similar at day 1, and reduced 2 and 3 days after
infection. At day 3 the reduction was approximately 1 log (90%).
Results at day 3 are presented as percentage of control cells with
significances (Figure 1E). In order to investigate if viral entry into
PBL is affected by SKI-II, we first measured if expression of the
MV receptor CD150 is altered by SKI-II. This was not the case
after 1, 24, and 48 h of treatment with 1 and 5 µM of the inhibitor
(not shown). Then we did a virus uptake assay and quantified
the percentage of infected (viral eGFP-positive) cells at day 1
after infection by flow cytometry. The percentage of infected cells
(and thus virus uptake) was not reduced by SKI-II, but there was
rather a tendency (not significant) toward increased virus uptake
FIGURE 1 | SKI-II inhibits MV replication in primary human PBL. The stimulation, infection, and viability of the PBL without and with PHA (2.5 µg/ml) for 24 h was
controlled by flow cytometry measuring the expression of CD69, viral eGFP, and propidium iodide (PI). An example of infected and uninfected PBL in the presence
and absence of PHA is shown in panel (A). Panel (B) shows a comparison of the MV titer produced by unstimulated and PHA-stimulated PBL (1 × 106 cells) as
determined at day 2 after infection at a MOI of 0.1 (n = 4; with ∗P ≤ 0.05) using Vero-hSLAM cells for titration. (C) PI incorporation assay as control for the viability of
the cells. PHA-stimulated PBL were treated for 48 h with SKI-II as indicated, dead cells were stained with PI, and percentages of living cells determined by flow
cytometry (normalized to DMSO control: 100%). (D) Primary human PBL were stimulated with PHA and 1 h pretreated with 0.2% DMSO as mock-treated control
(ctrl) or 1 and 5 µM SKI-II prior to infection with MV (MOI = 0.1). Newly synthesized infectious virus (cell bound plus supernatant) was titrated using Vero-hSLAM cells
1, 2, and 3 days after infection (n = 6 with PBL from six independent blood donors). (E) Virus titers at day 3 after infection in the presence of SKI-II (same data as in
panel D) were significantly reduced (Student’s t-test with ∗∗∗P < 0.001) and are presented as percentage of mock-treated control. (F) To measure the virus uptake
by PBL, cells were pretreated with 0.2% DMSO (=0 µM inhibitor) or increasing concentrations of SKI-II as indicated for 1 h prior to infection with MV (MOI = 0.5). The
percentage of infected eGFP-positive cells was quantified by flow cytometry 24 h after infection and is presented as percentage of DMSO (=0 µM inhibitor) control.
CTRL is the negative control without virus. ∗∗P ≤ 0.01.
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(Figure 1F). These results show that virus uptake is not impaired
by SKI-II, but that intracellular virus replication is reduced later
(at days 2 and 3) after infection.
Effects of Other Inhibitors of the
Sphingolipid Metabolism
Having observed this inhibition of MV replication by the
inhibitor of the SphKs, we wondered if inhibition of other
enzymes of the sphingolipid metabolism may also influence
virus replication. While inhibition of the sphingomyelinases
is supposed to reduce cellular ceramide content, inhibition of
the ceramidase should increase the amount of ceramide in the
cell. We therefore investigated the effects of the well-established
inhibitors of acid and neutral sphingomyelinases, amitriptyline,
and GW4869, respectively, and of the acid ceramidase, ceranib-
2 (Figure 2A). The toxicity of the inhibitors was determined
and the concentrations used accordingly (Figure 2F; not shown
for amitriptyline and GW4869). Analyzing the effects on MV
replication in PBL, we found that amitriptyline and GW4869
had no inhibitory effect (Figures 2B,C). Interestingly, GW4869
even had a replication stimulating effect within the first 24 h
after infection, which at days 2 and 3 after infection was
not detected any more. In contrast to the sphingomyelinase
inhibitors, ceranib-2 inhibited MV replication at days 2 and 3
after infection (Figure 2D). At day 3 after infection, 0.5 and 1 µM
ceranib-2 inhibited MV replication in PBL by approximately
90% (Figure 2E). The viability of the PBL was not affected at
these concentrations of ceranib-2 (Figure 2F). CD150 expression
was not altered in dependency of ceranib-2 after 1, 24, and
48 h of treatment (not shown). Determining virus uptake in the
presence of ceranib-2 we found, similar as with the inhibitor SKI-
II, that the percentage of MV-infected cells 24 h after infection
was not reduced, but rather slightly increased with increasing
concentrations of ceranib-2 (Figure 2G). Thus, inhibition of the
acid ceramidase in primary human PBL had very similar effects
on MV replication as inhibition of SphKs.
Sphingolipid Composition in PBL After
Treatment With the Inhibitors Ceranib-2
and SKI-II
Based on their similar effects, the question arises of whether both
inhibitors (SKI-II and ceranib-2) might act via similar or different
mechanisms on MV replication, and which sphingolipids might
potentially act as signaling molecules. To investigate the inhibitor
effects on the sphingolipid rheostat, we treated PHA-stimulated
PBL with these inhibitors and quantified SMs, ceramides, Sph,
and S1P by LC–MS/MS (Figure 3). For the analysis we chose
1 µM ceranib-2 and 5 µM SKI-II, because these concentrations
led to good inhibition of MV infection. Ceranib-2 had no
significant effect on SM and ceramide levels except ceramide C20
which was slightly increased at 24 h (Figure 3F). Surprisingly,
5 µM SKI-II caused significant increases in total ceramide and
C16, C18, C20, C22, and C24:1 ceramides. As expected, SKI-
II treatment reduced S1P concentrations in PBL (Figure 3K).
Likewise, there was a tendency that SKI-II led to increased Sph
concentrations, which however was not significant due to the
high variability between blood donors (Figure 3J).
SKI-II and Ceranib-2 Inhibit MV
Replication in BJAB Cells
Because variations between primary PBL from different donors
may have hampered the achievement of more significant results,
we decided to use a human B cells line, BJAB, to analyze effects
of the inhibitors. However, before doing so, we confirmed that
both inhibitors reduce MV replication similarly in BJAB cells as
in primary PBL. Treatment of BJAB cells with 1 or 2 µM SKI-
II led to a dose-dependent reduction of newly synthesized virus
at days 1, 2, and 3 after infection with MV (Figure 4A). Higher
concentrations of SKI-II were not used because BJAB cells were
more sensitive to SKI-II than primary PBL and approximately
80% died in the presence of 10µM SKI-II (Figure 4B). In contrast
to primary PBL (Figure 1D), the titration of newly synthesized
virus from infected BJAB cells showed that SKI-II reduced viral
titers already within the first 24 h after infection (Figures 4A,G),
while this reduction was generally not as pronounced as in
primary cells (Figures 1A,E). Investigating viral uptake, similarly
as in PBL (Figure 1F) and in spite of the titer reduction, the
percentage of infected cells 24 h after infection was not reduced
with increasing concentrations of SKI-II (Figure 4C). Thus,
virus uptake was not affected by SKI-II, but intracellular viral
replication was inhibited.
Using the acid ceramidase inhibitor, there was a clear
reduction of newly synthesized viral titers in the presence of 1 or
2 µM ceranib-2 (Figure 4D). Higher concentrations of ceranib-2
(3–10 µM) led to a reduction of the viability (Figure 4E). Virus
uptake was not affected by 1 or 2 µM ceranib-2 (Figure 4F). As
observed with SKI-II, MV replication was reduced by ceranib-
2 in BJAB cells already at day 1. Inhibition was, however, more
pronounced at day 3 (Figure 4H). Taken together, both inhibitors
impaired MV replication in BJAB cells similarly as observed in
primary PBL, although the inhibitory effects emerged faster in
BJAB cells being detected already at day 1 after infection.
Sphingolipid Composition in BJAB Cells
Treated With Inhibitors in the Presence
and Absence of MV Infection
For the sphingolipid analysis in BJAB cells we chose 3 µM
ceranib-2 in order to see clearer effect on ceramide levels than in
PBL, and 3 µM SKI-II. Treatment of the cells with ceranib-2 led
to reduced levels of total SMs and C16 SM at 48 h in the presence
or absence of infection (dark and light blue bars) in comparison
to the DMSO control (gray bar; Figure 5A), while total ceramide
levels were increased after 6, 24, and 48 h (Figure 5C). Increased
ceramide levels were found for total ceramide, C16, and C24:1,
but not for C18, C20, C22, and C24 ceramides. Interestingly, MV
infection and ceranib-2 treatment led to increased S1P levels at
6 h (Figure 5K). SKI-II treatment led to reduced total SM, C16
SM levels, total ceramide, C16, and C24: levels at 48 h in the
absence and presence of infection (Figures 5A–I; dark and light
orange bars). In addition, Sph was increased at 6 h after infection
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FIGURE 2 | Effects of other inhibitors of the sphingolipid metabolism: inhibition of MV replication by the acid ceramidase inhibitor ceranib-2. (A) Schematic
representation of a part of the sphingolipid metabolism with involved enzymes (the biosynthesis pathway of ceramides from serine and palmitoyl-CoA and
modification pathways to ceramide-1-phosphate and glucosyl-ceramides and complex glycosphingolipids are not shown). NSM, neutral sphingomyelinase; ASM,
acid sphingomyelinase; SKI-II, sphingosine kinase inhibitor 2; S1P, sphingosine-1-phosphate. (B–D) Primary human PBL were stimulated with PHA (2.5 µg/ml) for
24 h and pretreated with DMSO vehicle (CTRL) or increasing concentrations of inhibitor 1 h prior to infection with MV (MOI = 0.1). Newly synthesized infectious virus
(cell bound plus supernatant) was titrated using Vero-hSLAM cells 1, 2, and 3 days after infection. PBL were treated with amitriptyline (2 and 10 µM; n = 4; B),
GW4869 (0.2 and 1.0 µM; n = 4; C), and ceranib-2 (0.1, 0.5, and 1 µM; n = 6 with PBL from independent blood donors; D). (E) Virus titers at day 3 after infection in
the presence of ceranib-2 are significantly reduced. Standard deviations are shown. The statistical evaluation was done using Student’s t-test. (F) The viability of the
PBL was controlled using propidium iodide incorporation assay. (G) To measure virus uptake by PBL, cells were pretreated with increasing concentrations of
ceranib-2 as indicated for 1 h prior to infection with MV (MOI = 0.5). The percentage of infected eGFP-positive cells was quantified by flow cytometry 24 h after
infection and is presented as percentage of DMSO (=0 µM inhibitor) control. CTRL is the negative control without virus.
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FIGURE 3 | Sphingolipid composition in primary human PBL after treatment with the inhibitors ceranib-2 and SKI-II. PBL were treated for 6, 24, and 48 h with
DMSO 0.2% as vehicle control (gray), or 1 µM ceranib-2 (blue) or 5 µM SKI-II (orange). The samples (8 × 106 cells per sample) were processed for analysis of
sphingomyelins (total SM and C16 SM), ceramides (total Cer, C16, C18, C20, C22, C24, C24:1), sphingosine, and S1P by mass spectrometry. Results from PBL of
three independent donors (n = 3) were normalized to the mean amount of total SM measured (A) and are presented as pmol/sample, as indicated (A–K).
∗ represents significant differences calculated by Student’s t-test (n = 3).
(Figure 5J), while the S1P concentrations were decreased by
SKI-II at 6, 24, and 48 h (Figure 5K).
In order to have a closer look at the MV-induced increase
of S1P at early times after infection (Figure 5K), we did an
additional experiment analyzing sphingolipids at 0.5, 1, 2, 6, and
24 h after infection in the presence and absence of inhibitors.
Here we observed increased total ceramide concentrations
shortly after treatment with the inhibitors (Figure 5L), and a
strong S1P increase after 0.5–6 h after MV infection also in
the presence of ceranib-2, which, however, was not observed
in the presence of SKI-II (Figure 5M). Thus, SKI-II prevented
the transient increase of S1P induced by the MV infection.
In summary these data in BJAB cells showed that ceranib-
2 led to clearly increased ceramide levels, while SKI-II led
to decreased levels of S1P and some ceramide species. The
data suggest that in these cells ceranib-2 may act antivirally
via the increase in ceramide concentrations, whereas SKI-
II may predominantly act antivirally via the reduction of
S1P concentrations.
Reduced Metabolic Activity in
Inhibitor-Treated Lymphocytes Affects
MV Replication
One common effect of increased ceramide concentrations
as well as decreased S1P concentrations is to impair cell
metabolism and mTORC1 activity (Dobrowsky et al., 1993;
Mukhopadhyay et al., 2009; Apostolidis et al., 2016), while
efficient MV replication in PBL depends on mTORC1 activity
(Tiwarekar et al., 2018). We therefore investigated if the
inhibitors ceranib-2 and/or SKI-II may lead to reduced mTORC1
activity. We used the phosphorylation of p70 S6K as marker
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FIGURE 4 | Continued
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FIGURE 4 | SKI-II and ceranib-2 inhibit MV replication in BJAB cells. BJAB cells were pretreated with DMSO 0.2% as vehicle control or 1 and 2 µM SKI-II (A) and
ceranib-2 (D), prior to infection with MV (MOI = 0.1), and newly synthesized virus was titrated using Vero-hSLAM cells. The viability of the BJAB cells was determined
by propidium iodide incorporation by FACS in the presence of increasing concentrations of SKI-II (B) and ceranib-2 (E). To determine the effect of the inhibitors on
virus uptake, BJAB cells were treated with inhibitors for 1 h prior to infection with MV (MOI = 0.1). The percentage of infected eGFP-positive BJAB cells in the
presence of increasing concentrations of SKI-II (C) and ceranib-2 (F) was quantified by flow cytometry 24 h after infection and is presented as percent of DMSO
control (=0 µM inhibitor). The reductions in viral titers by SKI-II and ceranib-2 (same data as in panels A,D) are shown separately for days 1, 2, and 3 after infection
and after treatment of cells with SKI-II (G) and ceranib-2 (H) to demonstrate more clearly the inhibitor effects at different days and to show variations with
significances. The statistical evaluation was done using the Student’s t-test.
for mTORC1 activity. We found that ceranib-2 reduced
the phosphorylation of p70 S6K in comparison to DMSO-
treated controls in PBL, and that both inhibitors, ceranib-
2 and SKI-II, reduced the phosphorylation of p70 S6K in
BJAB cells (Figures 6A,B). These results suggest that both
inhibitors act at least by one common pathway reducing the
metabolic activity of the cells, which reduces the capacity
to replicate MV.
In addition, it is known that S1P also targets and activates
chaperones such as GRP94 and Hsp90, which among other effects
enable NF-kB activation (Xia et al., 2002; Alvarez et al., 2010;
Park et al., 2015, 2016), and that Hsp90 activity is required for
the replication of a number of viruses including MV (Connor
et al., 2007; Smith et al., 2010; Bloyet et al., 2016; Katoh et al.,
2017). Therefore, we tested the effect of the Hsp90 inhibitor 17-
AAG in primary human PBL. Treatment of PBL with 0.5 and
1 µM 17-AAG strongly reduced viral titers 2 and 3 days after
infection, but not yet at day 1 after infection (Figure 6C). This
observed kinetic of inhibition was similar to that observed with
the inhibitors SKI-II (Figure 1D) and ceranib-2 (Figure 2D)
in PBL. The viability and virus uptake were not affected by
17-AAG (Figures 6D,E).
DISCUSSION
The two inhibitors ceranib-2 and SKI-II have been described
as compounds with excellent potential for development as new
anticancer drugs (French et al., 2003; Draper et al., 2011;
Aurelio et al., 2016). SphKs are upregulated in many cancers
and thought to play a key role in disease progression through
increases in S1P and decreases in ceramide and Sph levels,
promoting tumor growth and survival (Santos and Lynch,
2015). Acid ceramidase is highly upregulated in breast tumors
and treatment with ceranib-2 significantly induced apoptosis in
human breast cancer cell lines (Vethakanraj et al., 2018). In
mice, ceranib-2 was found to delay tumor growth in a syngeneic
tumor model without hematologic suppression or overt signs
of toxicity (Draper et al., 2011). In contrast to cancer cells,
normal primary cells are less prone to induction of apoptosis
and cell death upon treatment with such inhibitors. This led
us to the hypothesis that these inhibitors could eventually be
applied against viral infections without damaging primary cells
including antiviral lymphocytes. Indeed, we found that already
relatively low concentrations of SKI-II (1 µM) and ceranib-
2 (0.5 µM) reduced MV replication in primary PBL, while
the expression of the MV receptor CD150 and viral uptake
was not altered.
That increased ceramide can have an antiviral role has been
described earlier for various viruses such as HIV (Finnegan et al.,
2004), hepatitis B virus (HBV) (Tatematsu et al., 2011), Dengue
virus (Perera et al., 2012), and IAV (Hidari et al., 2006; Tafesse
et al., 2013; Soudani et al., 2019). In the case of HIV, this was
mediated through a reduction in virus entry and perturbation
of host cell membrane structure leading to the production of
non-infectious viral progeny, and in the case of IAV through
impaired glycoprotein transport and maturation of viral particles.
However, on the other hand, sphingolipids including ceramides
may also be supportive for virus replication as in the case
of hepatitis C and West Nile virus (Zhang et al., 2019). Our
sphingolipid analyses after treatment of cells with SKI-II and
ceranib-2 led to different results for PBL and BJAB cells. In
PBL, SKI-II increased the concentrations of some ceramides and
ceranib-2 had no significant effect. In BJAB cells, SKI-II decreased
the concentration of some ceramides, while ceranib-2 led to
an increase. Furthermore, SKI-II reduced S1P concentrations
in PBL and BJAB cells. Thus, because of these findings and
because intracellular signaling effects of ceramides and S1P
may be locally limited events (for example at lysosomes or the
endoplasmic reticulum), these results unfortunately did not allow
clear conclusions. Interestingly, both, increased ceramide as well
as decreased S1P concentrations, reduce the mTORC activity as it
is known that ceramide acts on the SET protein and decreases
mTORC activity via the phosphatase PP2A (Dobrowsky et al.,
1993; Li et al., 1996; Neviani et al., 2005; Trotta et al., 2007;
Mukhopadhyay et al., 2009; Shi, 2009; Oaks and Ogretmen,
2014) and that S1P affects mTORC activity via Hsp90 and
raptor (Delgoffe et al., 2009). As demonstrated for regulatory T
cells, dephosphorylation by PP2A inactivates mTORC1 and thus
reduces the cell metabolism including protein translation and
lipid synthesis (Apostolidis et al., 2016). Among others, mTORC1
regulates the ribosomal S6 protein kinase-1, of which due to
alternative translation two isoforms are known in mammalian
cells, p85 and p70. The mTOR kinase phosphorylates and thereby
activates p70 at T389 and p85 at T412 (Ruvinsky and Meyuhas,
2006). Now we found that treatment of cells with ceranib-2
reduced the phosphorylation of p70 S6K in PBL and that SKI-
II reduced p70 S6K phosphorylation in PBL and BJAB cells
indicating reduced mTORC1 activity. Because MV replication
requires mTORC activity (Tiwarekar et al., 2018), it is likely that
this is a common effect of the inhibitors affecting MV replication.
We cannot exclude other (side-)effects of the inhibitors; however,
the main point of the paper remains that the inhibitors affect
MV replication. The finding suggests that the inhibitor-induced
reduction of the MV replication is at least partially due to this
reduction in mTORC1 activity.
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FIGURE 5 | Sphingolipid composition in BJAB cells after treatment with the inhibitors ceranib-2 and SKI-II and infection with MV. The sphingolipid composition was
determined in MV-infected (black bars; MOI = 0.5) and uninfected control (0.2% DMSO)-treated (gray bars) BJAB cells (1 × 106 per sample), in 3 µM
ceranib-2-treated infected (dark blue) and uninfected (light blue), and in 3 µM SKI-II-treated infected (dark orange) and uninfected (light orange) BJAB cells. Results
for total sphingomyelins (SM), C16 SM, ceramides (total Cer, C16, C18, C20, C22, C24, C24:1), sphingosine (Sph), and S1P are presented as pmol/sample per
1 × 106 cells as indicated (A–M). Stars in panels A–K designate significant (∗P ≤ 0.05) differences in comparison to control (0.2% DMSO-treated) cells (n = 3;
Student’s t-test). In panels L,M (n = 1), the significances between treatment groups were calculated by paired T-test and one-way ANOVA. In panel L, the DMSO
control values (0–6 h) were significantly different from MV + ceranib-2- and ceranib-2-treated cell values (P = 0.001 and P = 0.002, respectively). In panel M, the
DMSO control values were significantly different from MV and MV + ceranib-2-treated cell values (P = 0.04 and P = 0.007, respectively).
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FIGURE 6 | Ceranib-2 and SKI-II-mediated reduction of p70 S6K phosphorylation, and inhibition of MV replication by the Hsp90 inhibitor 17-AAG. Western blots
from cell extracts of human primary PBL (A) and BJAB cells (B) which were treated with 0.2% DMSO as control, 3 µM ceranib-2, and 5 µM SKI-II for 2, 6, 12, and
24 h as indicated were developed with antibodies against phosphorylated p70 S6K (also detecting p85), total p70 S6K, and GAPDH. Quantifications of
phosphorylated p70 S6K related to GAPDH of three blots of PBL from independent blood donors and BJAB of independent experiments are shown. (C) PBL were
treated with increasing concentrations of the Hsp90 inhibitor 17-AAG, infected with MV at a MOI of 0.1, and newly synthesized virus titrated after 1, 2, and 3 days
using Vero-hSLAM cells (n = 4). (D) Viability and virus uptake (E) was assessed as described (n = 3).
We also found that MV infection led to a strong S1P increase
between 0.5 and 6 h after infection, which was prevented by SKI-
II and thus a potential S1P anti-apoptotic/pro-survival signal that
may support MV replication is not provided. S1P and SphK1
were demonstrated to signal intracellularly via interaction with
TRAF2, RIP1 to activate Hsp90 and NF-κB (Xia et al., 2002;
Alvarez et al., 2010; Park et al., 2015, 2016). Thus, SKI-II prevents
a signal that the virus itself induces in order to support its
own replication. Interestingly, the chaperone Hsp90 is required
for the function of polymerases of many viruses including MV
(Connor et al., 2007; Smith et al., 2010; Bloyet et al., 2016;
Katoh et al., 2017). In Vero and HeLa cells and brain slices of
MV-susceptible mice it has been observed that Hsp90 inhibition
impairs MV replication (Bloyet et al., 2016). Inhibition or lack of
Hsp90 is preventing the proper folding of newly synthesized viral
polymerases and facilitates their degradation (Bloyet et al., 2016).
Because S1P regulates Hsp90 activity, it is likely that the SKI-
II-mediated decrease in S1P concentrations also impairs Hsp90
in PBL, which may contribute to the observed inhibition of
MV replication. We showed here that Hsp90 inhibition in PBL
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strongly reduced MV replication at days 2 and 3 after infection,
but did not affect MV replication at day 1. This kinetic of
inhibition is typically observed when functional viral polymerases
have been brought into the cell with infectious viral particles, but
newly synthesized viral polymerases at later times after infection
remain non-functional (Bloyet et al., 2016). In the presence
of SKI-II and ceranib-2, we observed similar kinetics of the
inhibition of the synthesis of new viruses in primary PBL. It is not
clear if and how ceranib-2 may influence Hsp90 activity; however,
it is probably part of the SKI-II-mediated inhibition of MV in
PBL. This might be different in BJAB cells, which responded
faster (already at day 1) to SKI-II (and ceranib-2).
A number of reports have described ceramide interacting
proteins such as the anti-oncogene p53 (Fekry et al., 2018),
ceramide activated protein kinase (CAPK) (Huwiler et al., 1996),
protein kinase C-ζ (PKCζ) (Wang et al., 2005), cathepsins
(Heinrich et al., 1999), and the ribosomal voltage dependent
anion channel 2 (VDAC2) (Dadsena et al., 2019), which can
induce apoptosis or other types of cell death. Predominantly C18
ceramide has been reported to interact with the SET (I2PP2A)
protein and to inhibit its activity, which leads to an activation of
the serine/threonine phosphatase PP2A, which dephosphorylates
and inactivates the anti-apoptotic protein BCL2 (Dobrowsky
et al., 1993; Li et al., 1996; Neviani et al., 2005; Trotta et al.,
2007; Mukhopadhyay et al., 2009; Oaks and Ogretmen, 2014).
For SKI-II it has been described mainly for cancer cells that
this inhibitor can also induce cell death (Leroux et al., 2007;
LeBlanc et al., 2015; Yang et al., 2015). Thus, increased ceramide
concentrations, as well as decreased S1P concentrations can
induce apoptosis or other forms of cell death (Hannun and
Obeid, 2008; Young et al., 2013; Oaks and Ogretmen, 2014). In
our study, low concentrations of the inhibitors (1 µM SKI-II
and 0.5 µM ceranib-2), which induced <5% dead PBL, clearly
reduced MV replication. Thus, this suggested that cell death is
not responsible for the observed reduction in MV replication.
CONCLUSION
In summary, our data indicate that MV replication is reduced
by inhibitors of the acid ceramidase and SphKs in primary
human PBL and suggest that viral replication is impaired
by several mechanisms regulated by sphingolipid-mediated
signaling pathways. We can add the aspect that the inhibitors
SKI-II and ceranib-2 affect the activities of mTORC1 and Hsp90,
and thus reduce MV replication. Future work is required to
reveal the exact mechanisms involved and to optimize the use
of compounds regulating sphingolipid metabolism in order to
inhibit virus replication while maintaining a functional antiviral
immune response in vivo.
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